Precision BioSciences Q2 net loss narrows to $11.9M; FDA clarity on azer-cel; cash through Q1 2025

PRECISION BIOSCIENCES INC

2023-Q2 EPS reported -$0.33 revenue$28,569,000

Net loss of $11.9M ($0.10 per share) vs $31.0M ($0.46) in Q2 2022; revenue $19.8M from $3.8M on Prevail amendment.
Cash and equivalents $137.8M; expected runway through Q1 2025 without additional funding.
FDA Type B meeting provided clarity on azer-cel registration path; partnering discussions underway for cell therapy assets.
In vivo gene editing programs progressing: PBGENE-HBV plans IND/CTA in 2024; PBGENE-DMD shows proof-of-concept; Novartis and Prevail collaborations ongoing.
Company to host In Vivo Gene Editing R&D Day on September 12, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

PRECISION BIOSCIENCES INC reported financial results for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 4, 2023, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

PRECISION BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0000950170-23-038328

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.